ARDent about acetylation and deacetylation in hypoxia signalling

Trends in Cell Biology

Volumn 16, Issue 12, 2006, Pages 616-621

  Bilton, Rebecca ^a,b   Trottier, Eric ^a   Pouysségur, Jacques ^a   Brahimi Horn, M Christiane ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ARREST DEFECTIVE 1 ENZYME; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; UNCLASSIFIED DRUG;

ACETYLATION; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ARTICLE; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEACETYLATION; ENZYME INHIBITION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HYPOXIA; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

ACETYLATION; ACETYLTRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DRUG DESIGN; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 33751344759     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2006.10.002     Document Type: Article

References (53)

1. Brahimi-Horn C., et al. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell. Signal. 17 (2005) 1-9
2. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9 (2003) 677-684
3. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
4. Pouyssegur J., et al. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
5. Schofield C.J., and Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5 (2004) 343-354
6. Jeong J.W., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
7. Bannister A.J., and Miska E.A. Regulation of gene expression by transcription factor acetylation. Cell. Mol. Life Sci. 57 (2000) 1184-1192
8. Polevoda B., and Sherman F. Composition and function of the eukaryotic N-terminal acetyltransferase subunits. Biochem. Biophys. Res. Commun. 308 (2003) 1-11
9. Whiteway M., et al. The yeast ARD1 gene product is required for repression of cryptic mating-type information at the HML locus. Mol. Cell. Biol. 7 (1987) 3713-3722
10. Whiteway M., and Szostak J.W. The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell 43 (1985) 483-492
11. Gautschi M., et al. The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol. Cell. Biol. 23 (2003) 7403-7414
12. Ingram A.K., et al. Genetic manipulation indicates that ARD1 is an essential N(infinity)-acetyltransferase in Trypanosoma brucei. Mol. Biochem. Parasitol. 111 (2000) 309-317
13. Williams B.C., et al. Two putative acetyltransferases, san and deco, are required for establishing sister chromatid cohesion in Drosophila. Curr. Biol. 13 (2003) 2025-2036
14. Arnesen T., et al. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem. J. 386 (2005) 433-443
15. Arnesen T., et al. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene 25 (2006) 4350-4360
16. Fisher T.S., et al. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J. Biol. Chem. 280 (2005) 17749-17757
17. Arnesen T., et al. Characterization of hARD2, a processed hARD1 gene duplicate encoding a human protein N-alpha-acetyltransferase. BMC Biochem. 7 (2006) 13
18. Tribioli C., et al. Isolation of new genes in distal Xq28: transcriptional map and identification of a human homologue of the ARD1 N-acetyl transferase of Saccharomyces cerevisiae. Hum. Mol. Genet. 3 (1994) 1061-1067
19. Kim S.H., et al. Characterization of ARD1 variants in mammalian cells. Biochem. Biophys. Res. Commun. 340 (2006) 422-427
20. Sanchez-Puig N., and Fersht A.R. Characterization of the native and fibrillar conformation of the human Nalpha-acetyltransferase ARD1. Protein Sci. 15 (2006) 1968-1976
21. Bilton R., et al. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J. Biol. Chem. 280 (2005) 31132-31140
22. Sugiura N., et al. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J. Biol. Chem. 278 (2003) 40113-40120
23. Arnesen T., et al. Interaction between HIF-1alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1alpha. FEBS Lett. 579 (2005) 6428-6432
24. Yoo Y.G., et al. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J. 25 (2006) 1231-1241
25. Chang C.C., et al. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J. Natl. Cancer Inst. 98 (2006) 984-995
26. Lin S., et al. Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol. Pharmacol. 66 (2004) 612-619
27. Qian D.Z., et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1{alpha}. Cancer Res. 66 (2006) 8814-8821
28. Fath D.M., et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J. Biol. Chem. 281 (2006) 13612-13619
29. Murray-Rust T.A., et al. Purified recombinant hARD1 does not catalyse acetylation of Lys(532) of HIF-1alpha fragments in vitro. FEBS Lett. 580 (2006) 1911-1918
30. Tanimoto K., et al. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19 (2000) 4298-4309
31. Lee K.H., et al. Differential responses of two degradation domains of HIF-1alpha to hypoxia and iron deficiency. Biochimie 88 (2006) 163-169
32. Chun Y.S., et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res. 63 (2003) 8700-8707
33. Deroanne C.F., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21 (2002) 427-436
34. Kim M.S., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7 (2001) 437-443
35. Qian D.Z., et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12 (2006) 634-642
36. Bolden J.E., et al. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
37. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
38. Mahon P.C., et al. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
39. Kato H., et al. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J. Biol. Chem. 279 (2004) 41966-41974
40. Bali P., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280 (2005) 26729-26734
41. Isaacs J.S., et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277 (2002) 29936-29944
42. Kong X., et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1{alpha}. Mol. Cell. Biol. 26 (2006) 2019-2028
43. Kasper L.H., et al. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J. 24 (2005) 3846-3858
44. Fluge O., et al. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene 21 (2002) 5056-5068
45. Line A., et al. Serological identification and expression analysis of gastric cancer-associated genes. Br. J. Cancer 86 (2002) 1824-1830
46. Arnesen T., et al. Expression of N-acetyl transferase human and human arrest defective 1 proteins in thyroid neoplasms. Thyroid 15 (2005) 1131-1136
47. Neuwald A.F., and Landsman D. GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem. Sci. 22 (1997) 154-155
48. Mullen J.R., et al. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J. 8 (1989) 2067-2075
49. Park E.C., and Szostak J.W. ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity. EMBO J. 11 (1992) 2087-2093
50. Arnesen T., et al. Cloning and characterization of hNAT5/hSAN: An evolutionarily conserved component of the NatA protein N-alpha-acetyltransferase complex. Gene 371 (2006) 291-295
51. Arnesen T. HIF-1alpha & ARD1: enemies, friends or neither. Nat. Rev. Cancer 6 (2006) 249
52. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
53. Moehler T.M., et al. Angiogenesis in hematologic malignancies. Crit. Rev. Oncol. Hematol. 45 (2003) 227-244